“Azithromycin, and no antibiotic in general, is approved, much less recommended, for the treatment of Covid-19.” This was specified by the Italian drug agency Aifa, “regarding the recent press reports relating to the deficiency of azithromycin”, trade name Zithromax * in the originator version, “also following its excessive and improper use for Covid-19”. Read also Aifa points out that “from the checks carried out, the current shortage does not derive from exports or other distribution anomalies, but from the prescription of the drug outside the indications provided”. “Since the beginning of the pandemic – reminds the regulatory body national – Aifa strongly discouraged the use of azithromycin for Covid. As amply demonstrated by numerous and well-conducted clinical studies published in the best international journals “, the agency underlines,” there is no evidence that the use of ‘azithromycin has a protective effect on the evolution of Covid-19, neither in terms of reduction of transmission, nor of healing times, or of mortality. There is clear and unequivocal evidence for no longer using azithromycin or other antibiotics in the treatment of Covid-19, as clearly indicated by all international guidelines for the treatment of Sars-CoV-2 infection “. The AIFA recalls more generally that “antibiotics are not effective for the treatment of any viral infection, including seasonal flu” and that “the indiscriminate use of azithromycin or any other antibiotic, in addition to having no basis scientifically, exposes the dual risk of creating antibiotic deficiency conditions for those who actually need them to treat bacterial infections, and of increasing the risk of developing and spreading antibiotic-resistant bacteria “.